{"entity":{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","aka":[],"tldr":"San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer.","summary":"Robin Kate Kelley is a gastrointestinal medical oncologist at UCSF who focuses on liver and biliary cancers. She was first author of the 2023 Lancet report of KEYNOTE-966, in which pembrolizumab plus gemcitabine and cisplatin improved overall survival in advanced biliary tract cancer, and has led early trials of immunotherapy combinations in hepatocellular carcinoma, including the cabozantinib and atezolizumab study COSMIC-312.","asOf":"2026-09-18","links":[],"tags":["biliary","hcc","immunotherapy","trialist"],"related":[],"cancers":["intrahepatic-cholangiocarcinoma","biliary-tract-cancer","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-966-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastrointestinal oncologist, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Hepatocellular carcinoma","Biliary tract cancer","Immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelley%5BAuthor%5D"}],"papers":[]},"route":"/people/robin-kate-kelley/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}],"paper":[{"id":"paper-keynote-966-lancet-2023","kind":"paper","name":"KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer","route":"/key-papers/paper-keynote-966-lancet-2023/"}]}}